First Line Treatment for Advanced or Metastatic Pancreatic Cancer

IRB# 17094
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

IRB# 23124
A Phase Ib/II, Randomized Study of AVB-S6-500 plus Nab-paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma

IRB# 22141
A Phase I, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

IRB# 17094
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Serial Measurements of Molecular and Architectural Responses to Therapy

IRB# 15588
Serial Measurements of Molecular and Architectural Responses to Therapy

IRB# 20679
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

Cross-Disease Trials:

IRB# 20679
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment
GI Pancreatic - Metastatic

Localised

- **NeoAdjuvant**
  - IRB #19211: A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma

- **Adjuvant**
  - IRB #21614: NeoOptimize: An Open-Label, Phase II Trial To Assess The Efficacy Of Adaptive Switching Of mFolfirinox Or Gemcitabine/Nab-Paclitaxel As A NeoAdjuvant Strategy For Patients With Resectable And Borderline Resectable Pancreatic Cancer.
  - IRB# 24549: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
  - IRB# 17751: Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer

[https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result](https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result)
GI Pancreatic - Metastatic

Quality Improvement Trials:

IRB # 22619: A Phase II Trial of Pre-operative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula following Distal Pancreatectomy

IRB# 22413 Polyglycolic Acid Mesh to Prevent Pancreatic Fistula After Distal Pancreatectomy: A Multi-Center Efficacy Trial

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result